Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nanfeng; Luo, Suxia; Li, Zhen; Gu, Kangsheng; Lu, Jianwei; Xu, Jianming; Fan, Qingxia; Xu, Rui‐Hua; Zhang, Liangming; Li, Enxiao; Sun, Yuping; Yu, Guohua; Bai, Chunmei; Liu, Yong; Zeng, Jiangzheng; Ying, Jieer; Liang, Xinjun; Xu, Nong; Gao, Chao; Shu, Yongqian; Ma, Dong; Dai, Guanghai; Li, Shengmian; Deng, Ting; Cui, Yuehong; Fang, Jianmin; Ba, Yi; Shen, Lin

doi:10.1002/cac2.12214

Public

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Published in 癌症：英文版 • Oct 19, 2021

Authors:

Zhi Peng

Tianshu Liu

Jia Wei

Abstract

BACKGROUND: Current treatment options for human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in-situ hybridization-negative pa...

Subject

Medicine

Internal medicine

Adverse effect

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!